Close menu

Uwe Ahrens, Direktor, Altech Advanced Materials AG

Uwe Ahrens
Direktor | Altech Advanced Materials AG
Ziegelhäuser Landstraße 3, 69120 Heidelberg (DE)

Interview with battery pioneer Altech Advanced Materials: "We hit a nerve with potential partners and investors"

October 6th, 2022

  • battery technology
  • Batteries
  • E-cars

Cheaper, safer, better: Altech Advanced Materials has so far convinced the market with the attributes of its anode technology. Since September 2022, it has been clear that the Company also has well-developed ideas around stationary energy storage and wants to lead the Fraunhofer Institute's solid-state battery technology to market maturity together with the researchers. In an interview, Altech CEO Uwe Ahrens talks about the three business areas, the path to production and the special features of his Company.

Full interview

Dennis Karp, Executive Chairman, Manuka Resources

Dennis Karp
Executive Chairman | Manuka Resources
201-207 Kent Street, NSW 2000 Sydney (AU)

+61 2 72 532 020

Manuka Resources Interview: Where cash flows and blue sky potential come together

September 19th, 2022

  • Gold
  • Silver
  • Vanadium
  • Energy

ASX listed Manuka Resources combines the stability of a producer and the opportunity of a growth company. Its two projects producing gold and silver generate cash flows on the one hand yet have enormous potential for further development on the other - no wonder the gold resource in particular continues to grow despite increasing production volumes. Recently, the well-connected management team achieved another coup acquiring a very large iron sands and vanadium project in New Zealand. The South Taranaki Bight project (STB project) hosts a VTM iron sands deposit (vanadium, titanomagnetite iron sands) with outstanding PFS economics, unique environmental credentials and is scheduled to be in production within a few years. Even today, vanadium is to infrastructure projects and utility energy storage, what lithium is to electromobility, ie: absolutely critical. We talked to Dennis Karp, Executive Chairman of Manuka Resources, about the prospects and facts surrounding Manuka’s project portfolio.

Full interview

Brodie Sutherland, CEO, Tocvan Ventures

Brodie Sutherland
CEO | Tocvan Ventures
820 – 1130 West Pender St, V6E 4A4 Vancouver (CAN)

+ 1 403 829 9877

Interview with Tocvan Ventures: "High gold content and low costs have convinced professional investors despite the crisis”.

July 12th, 2022

  • Gold
  • Mexico
  • Heap-leaching
  • high grade
  • low cost

Tocvan Ventures has come up with several impressive developments in recent weeks: In addition to obtaining financing despite a challenging market environment, the gold prospector identified new zones of mineralization on both its projects in Mexico. The grades have caused a stir within the mining scene. In an interview, CEO and geologist Brodie Sutherland explains why Tocvan Ventures has two hot irons in the fire, what role Mexico plays as a location, and how the team intends to continue creating value in the future.

Full interview

Tim Daniels, CEO, Erin Ventures

Tim Daniels
CEO | Erin Ventures
645 Fort Street, Suite 203, BC V8W 1G2 Victoria (CAN)

Interview Erin Ventures: "Many megatrends involve boron, but the market is still in its infancy"

June 29th, 2022

  • boron
  • Climate Change
  • Oligopoly
  • Turkey
  • Turkye
  • Batteries

Batteries for electric cars, fuel cells, wind turbines, solar panels, LCD screens and fertilizers: Boron is versatile and hardly replaceable. So far, two players share 75% of the market and are making a killing. Erin Ventures has a boron project in Serbia and recently published convincing key economic data. The only other major players in Boron are the government owned Eti Maden in Turkey, and Rio Tinto in California. Thanks to the figures, Erin even managed to attract a joint venture partner, at the project level, in these challenging times to take on financing risks and minimize future dilution for shareholders. CEO Tim Daniels talks about the market for boron and the opportunities for Erin Ventures, which is only in the single digits.

Full interview

Joe Bleackley, CEO, Pathfinder Ventures Inc.

Joe Bleackley
CEO | Pathfinder Ventures Inc.
9451 Glover Road, PO, V1M 2R9 Box 610 Fort Langley, BC (CAN)

Interview with campsite operator Pathfinder Ventures: "We create unforgettable family experiences and set new standards."

June 27th, 2022

  • Camping
  • RV
  • Travel

Going out into nature in your own motorhome and switching off for a while has long since become a ritual for many families. Pathfinder Ventures currently operates three RV Resorts & campgrounds in British Columbia and has set itself the task of consolidating the predominantly family owned campground market, and also building new locations at the same time. In an interview, CEO, camping enthusiast Joe Bleackley explains how the Company plans to attract customers and investors alike and where Pathfinder Ventures plays to its strengths.

Full interview

Ryan McDermott, CEO, Phoenix Copper

Ryan McDermott
CEO | Phoenix Copper
OMC Chambers, Wickhams Cay 1, ROAD TOWN, VG1110 Virgin Islands (British) (GB)

Interview Phoenix Copper: Copper with certain advantages

April 29th, 2022

  • ESG
  • Copper
  • Canada

Phoenix Copper could go into production as early as 2023 and surprise the market with its production costs and other general conditions. In an interview, CEO Ryan McDermott explains why the Company doesn't believe in making a lot of promises, why the planned Empire Open Pit project doesn't anticipate any environmental impacts, and what other potential lies dormant in the Company.

Full interview

Bill Radvak, CEO, NervGen Pharma

Bill Radvak
CEO | NervGen Pharma
2955 Virtual Way, Suite 480, V5M 4X6 Vancouver, BC (CAN)

+1 604.537.2094

Interview NervGen Pharma: "We have a drug with the potential to treat Alzheimer's, MS, spinal cord injury and stroke".

April 14th, 2022

  • Biotech
  • Drug
  • Self-healing

Multiple sclerosis, Alzheimer's disease or even strokes have something in common with spinal cord injury: they damage the nervous system. This makes them all incredibly difficult to treat. But a therapeutic breakthrough finally seems possible. In the 1990s, Dr. Jerry Silver discovered the root cause for why debilitating damage to the central nervous system cannot be repaired. What was a revolutionary discovery at the time is now accepted science. The NervGen team, which has exclusively licensed the technology that came from Dr. Silver’s lab, is now at an exciting time in the development of a potentially paradigm changing milestone, based on his 30 years of important work. The breakthrough could come as early as next year. We talk about NervGen's approach and plans for a Nasdaq listing with NervGen Executive Chairman Bill Radvak.

Full interview

Dylan Ong, General Manager and Executive Director, Hong Lai Huat

Dylan Ong
General Manager and Executive Director | Hong Lai Huat
10 Bukit Batok Crescent, #13-05, The Spire, S658079 Singapore (SG)

+65 6861 0330

Interview Hong Lai Huat: Real estate in Cambodia promises high margins

April 6th, 2022

  • Real Estate
  • Cambodia
  • Singapore

Cambodia offers breathtaking beaches, the world wonder of the Angkor Wat temples and an emerging economy: the rating agency Fitch expects growth of 4.7% in 2022. In this interview, Dylan Ong, General Manager and Executive Director of Hong Lai Huat, explains the opportunities offered by Cambodia's real estate market, why the Group has an edge over other investors, and which joint venture could generate big fantasy as early as 2022.

Full interview

David Elsley, CEO, Cardiol Therapeutics

David Elsley
CEO | Cardiol Therapeutics
602-2265 Upper Middle Road East, L6H 0G5 Oakville (CAN)

+1 (289) 910-0850

Interview Cardiol Therapeutics: 'We have two potential blockbusters in our portfolio'

March 10th, 2022

  • Heart Disease
  • Covid-19
  • Myocarditis

In this interview, Cardiol Therapeutics’ President and CEO David Elsley explains the unique selling points of the Company’s lead product, CardiolRx™, an oral cannabidiol formulation pharmaceutically manufactured under cGMP. He explains why the upcoming clinical trials could result in exclusive multi-year distribution agreements, why the financing last November was a good decision, and how major funds from the U.S. currently stand by Cardiol Therapeutics.

Full interview

Terry Lynch, CEO, Power Nickel

Terry Lynch
CEO | Power Nickel
82 Richmond St East Suite 202, M5C 1P1 Toronto (CAN)

+1 416 900-5445

Power Nickel Interview: 'The coming quarters change everything.'

March 8th, 2022

  • Nickel
  • Battery Metals
  • Electromobility

A promising nickel project in Quebec, several gold properties in Canada and Chile, and a license agreement with Teck Resources that could yet provide surprises - Power Nickel's list of activities is long. But the Company is consolidating. As early as the second quarter, historical data is expected to be converted into an updated resource estimate for the flagship NISK project. Shareholders also stand to receive bonus shares later this year. Here is what Terry Lynch, CEO of Power Nickel, has in mind for 2022 and what the Company needs to do to be valued at CAD 800 million instead of CAD 15 million.

Full interview

Dr. Moutih Rafei, Director and VP of research and development, Defence Therapeutics

Dr. Moutih Rafei
Director and VP of research and development | Defence Therapeutics
1680 – 200 Burrard Street, V6C 3L6 Vancouver (CAN)

+1 (514) 947 2272

Defence Therapeutics Interview: 'Accum™ is the most sought-after multi-tool in the pharmaceutical industry.'

February 23rd, 2022

  • Cancer
  • Drug enhancer
  • platforms

The case of the German biotech CureVac has shown that costly projects often fail because of the finer details. Canadian biotech Defence Therapeutics has developed a drug enhancer with its patented Accum™ technology, which works with many technologies and, even on its own, has a highly toxic effect on cancer cells. Dr. Moutih Rafei, director and VP of research and development at Defence Therapeutics, explains in an interview how Defence Therapeutics is working toward upcoming Phase I trials around vaccines for breast and skin cancer, how else the versatile technology can be used, and to which pharma giants it has specific scientific tie-ins.

Full interview

Uwe Ahrens, Director, Altech Advanced Materials AG

Uwe Ahrens
Director | Altech Advanced Materials AG
Ziegelhäuser Landstraße 3, 69120 Heidelberg (DE)

Interview Altech Advanced Materials: "We make batteries in e-cars more powerful and more durable".

January 27th, 2022

  • Electromobility
  • Battery
  • E-Cars

Uwe Ahrens, director of Altech Advanced Materials, is convinced that e-cars will soon be cheaper than combustion engines. Ahrens and his team are pushing ahead with innovations and are not afraid of a price war in the battery industry. The reason: with its technology, the Company sees the potential to make batteries for e-cars significantly more powerful. Find out how this works and what other aces Altech Advanced Materials has up its sleeve in an interview with the experienced industry manager.

Full interview